ADVI Health Research Featured in Health Affairs
On July 31, 2026, the Health Affairs article, “The Collision Of 340B Pricing And Medicare Drug Price Negotiation,” referenced research from ADVI Health’s strategic analytics, value and economics (SAVEs) solution team on the overlap between Medicare Maximum Fair Price (MFP) and 340B claims. Citing ADVI’s Analysis of 340B modifier usage in Medicare Part D claims for IPAY 2026 and IPAY 2027 selected drugs, the Health Affairs article explores the operational challenges created by overlapping pricing programs and what they mean for manufacturers, providers, and the evolving Medicare landscape.
Read the full article and learn more about ADVI’s SAVEs insights and expertise.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.